Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010
Diagnosis and Management of Migraine
BMJ 312:1279-1283, Goadsby,P.J.&Olesen,J., 1996
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Effect of Calcitonin-Gene-Related Peptide in Pts with Delayed Postop Cerebral Ischaemia after Aneurysmal SAH
Europ CGRP Study Group, Lancet 339:831-8341992., , 1992
Effect of Calcitonin-Gene-Related Peptide on Postoperative Neurological Deficits after Subarachnoid Haemorrhage
Lancet 335:869-872, Johnston,F.G.,et al, 1990
Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache
Ann Neurol 28:183-187, Goadsby,P.J.,et al, 1990
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Essential Tremor
NEJM 378:1802-1810, Haubenberger, D.,et al, 2018
Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
EMA401, An Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, as a Novel Treatment for Postherpetic Neuralgia: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
Lancet 383:1637-1647, Rice, A.C.,et al, 2014
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Seizures on Hearing the Alarm Clock
Lancet 370:2172, Vollmar,C.,et al, 2007
Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Prophylactic Treatment of Migraine With an Angiotnesin II Receptor Blocker
JAMA 289:65-69, Tronvik,E.,et al, 2003
Treatment of Sporadic Hemiplegic Migraine with Calcium-Channel Blocker Verapamil
Neurol 60:120-121, Yu,W. &Horowitz,S.H., 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Hypersexuality in Patients with Dementia: Possible Response to Cimetidine
Neurol 54:2024, Wiseman,S.V.,et al, 2000
Migraine in Pregnancy
Neurol 53:S26-S28, Aube,M., 1999
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340995., Forestier,N.L.,et al, 1995
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Phenytoin and Ranitidine Interaction
Ann Int Med 120:892-893, Tse,C.S.T.&Iagmin,P., 1994
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Treatment of Migraine
Lancet 339:1207-1209, Lance,J.W., 1992
Ranitidine Pharmacokinetics and Adverse Central Nervous System Reactions
Arch Int Med 152:2325-2329, Slugg,P.H.,et al, 1992
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991